BioArctic AB revealed the publication of the findings from two phase-1 trials involving exidavnemab(ABBV-0805) in The Journal of Clinical Pharmacology.

SIFI revealed that the European Commission has granted approval for AKANTIOR® (polihexanide) for managing acanthamoeba keratitis (AK) in both adults and children aged 12 and over.

The European Commission grants approval to Celltrion’s SteQeyma® (CT-P43), a biosimilar version of Stelara® (ustekinumab), for treating several chronic inflammatory disorders.

Galapagos reveals FDA approval of its IND application for the Phase 1/2 ATALANTA-1 trial of CD19 CAR-T therapy, GLPG5101, in non-Hodgkin lymphoma that has relapsed or is refractory.

Moderna, Inc. (NASDAQ:MRNA) reported that the European Commission (EC) has approved mRESVIA® (mRNA-1345), an mRNA vaccine targeting respiratory syncytial virus (RSV), for marketing.

The company will commence a Phase III clinical trial aiming to investigate the effectiveness and safety of 9MW2821 in individuals with recurrent or metastatic cervical cancer (CC).

YolTech Therapeutics Administers First Patient Dose of YOLT-203 in Clinical Trial for Groundbreaking In Vivo Gene Editing Therapy for PH1.

FDA Approves Pfizer-BioNTech's Updated COVID-19 Vaccine for Ages 12 and Up; Grants Emergency Use for Ages 6 Months to 11 Years.

The European Commission has granted approval for BALVERSA® (erdafitinib) in treating adults with advanced or metastatic urothelial cancer.

This trial is investigating OMX-0407, a first-in-class, spectrum-selective SIK (salt-inducible kinase) inhibitor, in patients with advanced solid tumors.

Skye Bioscience Initiates Phase 2 CBeyond Trial for its Unique CB1 Inhibitor Nimacimab in Obesity Patients.

Sutro Biopharma has initiated and is currently enrolling participants for its global Phase 2 trial, REFRαME-L1, which tests luveltamab tazevibulin (luvelta) in NSCLC patients with Folate Receptor-α expression.